Last reviewed · How we verify
NCT04303650
The Relation Between Quadriceps Muscle Layer Thickness and Nitrogen Balance for Nutrition Monitoring
trial testing Ultrasound measurement of quadriceps muscle layer thickness in Trauma in 186 participants. Completed in 30 November 2023.
30 October 2023
Quick facts
| Lead sponsor | Zagazig University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 186 |
| Start date | 15 March 2020 |
| Primary completion | 30 October 2023 |
| Estimated completion | 30 November 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Ultrasound measurement of quadriceps muscle layer thickness
Conditions studied
- Trauma — all drugs for Trauma →
Sponsor
Zagazig University
Who can join
Adults 18 to 60, any sex, with Trauma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Loss of muscle mass is a major cause of intensive care unit-acquired weakness (ICU-AW) and is associated with delayed weaning; prolonged ICU and hospital stay and is an independent predictor of one year mortality. Theoretically, the best strategy to minimize muscle loss during ICU stay, is delivering an appropriate nutritional support. Studying the correlation between the sequential assessments of quadriceps femoris muscle layer thickness (QMLT) by the aid of Ultrasound in addition to the traditional method (NB) for assessment of nutritional status may be helpful to predict outcome and mortality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04303650
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Trauma
Currently open trials in the same condition.
- NCT07290634 — Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion · recruiting
- NCT07485231 — Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD · NA · recruiting
- NCT07473336 — The Effectiveness of RAPID-Based Psychological First Aid Training · NA · active not recruiting
- NCT07278505 — Study of Cannabidiol and Neuroimaging on Stress · Phase 1, PHASE2 · recruiting
- NCT02880163 — REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam · NA · recruiting
Other Zagazig University trials
Trials by the same sponsor.
- NCT07423676 — Comparison Between Two Drugs in Sedation of Upper GI Endoscopy · not yet recruiting
- NCT07418307 — Comparison Between Combined Biceps Femoris Short Head Block and Adductor Canal Block Versus Genicular Nerve Block · NA · not yet recruiting
- NCT07435025 — Surgery for Obstructed Gastric Carcinoma · NA · active not recruiting
- NCT07330375 — Effect of Intravenous Dexmedetomidine and Ketamine on Post-Operative Analgesia · Phase 3 · not yet recruiting
- NCT07309731 — Impact OF Cooled Versus Thermal Radiofrequency Denervation In Management Of Chronic Lumber Facet Joint Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04303650 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zagazig University
- Last refreshed: 5 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04303650.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing